Does Dosage Drive Durability? A Longitudinal Study on Digital Cognitive Training for Sustained Functional Independence.

Geriatr Gerontol IntSep 26, 2026
Clinical ResearchGeriatricsNeurology

Bruno Costa Poltronieri, Cíntia Monteiro Carvalho, Karin Reuwsaat et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the effects of digital cognitive training (DCT) on cognition and functionality in older adults with Mild Neurocognitive Disorder. Participants aged 60 or older received either 10 or 20 hours of DCT. The 20-hour group demonstrated significant improvements in functionality and cognitive measures, with benefits maintained at 3- and 6-month follow-ups.

Key findings

  • The 20-hour DCT group showed significant improvements in functionality and satisfaction.
  • Improvements in processing speed, verbal fluency, and inhibitory control were noted in the 20-hour group.
  • The 10-hour group also showed gains in processing speed and recognition.
  • Benefits from the 20-hour intervention were maintained at 3- and 6-month follow-ups.

Why it matters

Understanding the relationship between dosage and cognitive training outcomes is crucial for developing effective interventions for older adults with neurocognitive disorders. Sustained improvements in functionality can enhance quality of life.

Source

PubMed · PMID 42791030

Published in Geriatr Gerontol Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.